StockData
Corbus Pharmaceuticals Holdings, Inc. logo

Corbus Pharmaceuticals Holdings, Inc. (CRBP) stock

CRBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$3.01−0.37 (-10.81%)

Close on Nov 17, 2026Market cap $58.22MP/E –Yield –

Corbus Pharmaceuticals ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Corbus Pharmaceuticals's ebitda for the twelve months ending Jun 30, 2026 was -$106.68M. For fiscal 2025 it was -$85.08M. The highest annual figure on record is -$8.81M in fiscal 2015.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$85.08M–
FY2024Dec 31, 2024-$48.13M–
FY2023Dec 31, 2023-$44.44M–
FY2022Dec 31, 2022-$39.07M–
FY2021Dec 31, 2021-$54.99M–
FY2020Dec 31, 2020-$121.69M–
FY2019Dec 31, 2019-$76.37M–
FY2018Dec 31, 2018-$56.25M–
FY2017Dec 31, 2017-$32.31M–
FY2016Dec 31, 2016-$19.90M–
FY2015Dec 31, 2015-$8.81M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$36.14M–
Q1 FY2026Mar 31, 2026-$24.26M–
Q4 FY2025Dec 31, 2025-$21.92M–
Q3 FY2025Sep 30, 2025-$24.37M–
Q2 FY2025Jun 30, 2025-$19.10M–
Q1 FY2025Mar 31, 2025-$19.69M–
Q4 FY2024Dec 31, 2024-$12.47M–
Q3 FY2024Sep 30, 2024-$15.35M–
Q2 FY2024Jun 30, 2024-$10.84M–
Q1 FY2024Mar 31, 2024-$9.47M–
Q4 FY2023Dec 31, 2023-$9.96M–
Q3 FY2023Sep 30, 2023-$9.34M–
Q2 FY2023Jun 30, 2023-$8.03M–
Q1 FY2023Mar 31, 2023-$17.12M–
Q4 FY2022Dec 31, 2022-$10.61M–
Q3 FY2022Sep 30, 2022-$7.99M–
Q2 FY2022Jun 30, 2022-$12.15M–
Q1 FY2022Mar 31, 2022-$8.32M–
Q4 FY2021Dec 31, 2021-$9.79M–
Q3 FY2021Sep 30, 2021-$13.62M–
Q2 FY2021Jun 30, 2021-$16.44M–
Q1 FY2021Mar 31, 2021-$15.14M–
Q4 FY2020Dec 31, 2020-$20.53M–
Q3 FY2020Sep 30, 2020-$33.77M–
Q2 FY2020Jun 30, 2020-$37.82M-2132.2%
Q1 FY2020Mar 31, 2020-$29.57M–
Q4 FY2019Dec 31, 2019-$26.92M–
Q3 FY2019Sep 30, 2019-$24.94M–
Q2 FY2019Jun 30, 2019$1.86M–
Q1 FY2019Mar 31, 2019-$26.37M–
Q4 FY2018Dec 31, 2018-$17.44M–
Q3 FY2018Sep 30, 2018-$14.77M–
Q2 FY2018Jun 30, 2018-$12.27M–
Q1 FY2018Mar 31, 2018-$11.78M–
Q4 FY2017Dec 31, 2017-$10.80M–
Q3 FY2017Sep 30, 2017-$6.83M–
Q2 FY2017Jun 30, 2017-$7.26M–
Q1 FY2017Mar 31, 2017-$7.42M–
Q4 FY2016Dec 31, 2016-$7.54M–
Q3 FY2016Sep 30, 2016-$5.31M–

More Corbus Pharmaceuticals figures

See a number that looks wrong?